Evidence map›Paper›PMID 40333703›Full record

ArticlePloS one2025

A systematic analysis for disease burden, risk factors, and trend projection of Alzheimer's disease and other dementias in China and globally.

Siyu Liu, Daoying Geng

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Diabetes and Alzheimer's Disease.Journal of diabetes · 2025
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Siyu LiuRadiology Department, Huashan Hospital, Affiliated with Fudan University, Shanghai, China.
Daoying GengRadiology Department, Huashan Hospital, Affiliated with Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-7010-4556

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aims to provide improvement directions for aging societies by analyzing the disease burden, risk factors and trend forecasts of AD and other dementias (ADD) in China and globally from 1990 to 2021.

methodsData sourced from Global Burden of Disease 2021. We extracted indicators of disease burden and risk factors for ADD in people aged 40 years and older, including incidence, prevalence, deaths, disability-adjusted life years, years lived with disability and years of life lost. The annual percent change and average annual percent change over the past 32 years were analyzed by Joinpoint regression. Decomposition analysis was used to clarify the contribution of aging, population and epidemiological change. The directions of deaths and incidence in China and globally were predicted using ARIMA model for the next 15 years.

resultsThe disease burden of ADD in China is heavier than in most countries and regions. By 2021, China's disease burden has increased by three times, while the global disease burden has doubled. Females bear more burden but face lower mortality. Population growth is the main reason for the burden. Smoking, high fasting plasma glucose and high body-mass index are the three major risk factors, among which high fasting plasma glucose occupies a dominant position.

conclusionThe disease burden of ADD in China and globally is increasing daily and will remain high in the future. It is urgent to introduce some effective intervention measures to prevent such diseases as early as possible.

Indexed as

Alzheimer DiseaseCost of IllnessDementiaAdultAgedAged, 80 and overChinaDisability-Adjusted Life YearsFemaleGlobal Burden of DiseaseHumansIncidenceMaleMiddle AgedPrevalenceRisk Factors

Identifiers

PMID40333703
PMCPMC12057861

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.